GSK to buy US biotech firm IDRx for up to $1.15 billion | Reuters

2 days ago · British drugmaker GSK said on Monday that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical firm IDRx, which is developing a treatment for a rare type of …

$1.15
OFF

GSK To Buy US Biotech Firm IDRx For Up To $1.15 Billion | Reuters

2 weeks from now

2 days ago · British drugmaker GSK said on Monday that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical firm IDRx, which is developing a treatment for a rare type of …

reuters.com

100%
OFF

GSK Enters Agreement To Acquire IDRx, Inc. | GSK

2 weeks from now

2 days ago · Under the terms of the agreement, GSK will acquire one hundred percent (100%) of the outstanding equity interests (including all options and other incentive equity) in IDRx for up …

gsk.com

$1.15
OFF

GSK Acquiring US-Based IDRx For Up To $1.15 Billion - MSN

2 weeks from now

GSK (GSK) has agreed to acquire Boston-based IDRx for up to $1.15 billion as the British drugmaker looks to expand its gastrointestinal cancer portfolio, the companies said Monday.

msn.com

$1.15
OFF

GSK To Buy US Biotech Firm IDRx For Up To $1.15 Billion - MSN

2 weeks from now

(Reuters) -British drugmaker GSK said on Monday that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical firm IDRx, which is developing a treatment for a rare type of …

msn.com

100%
OFF

GSK Enters Agreement To Acquire IDRx, Inc. - BioSpace

2 weeks from now

2 days ago · Under the terms of the agreement, GSK will acquire one hundred percent (100%) of the outstanding equity interests (including all options and other incentive equity) in IDRx for up …

biospace.com

$1.15
OFF

GSK Buys American Firm Developing Therapy For Rare Tumours

2 weeks from now

GSK has agreed an acquisition worth up to $1.15 billion for IDRx, an American biopharmaceutical company. The FTSE 100 company said the deal would help it hit its target of increasing group …

thetimes.com

$1.15
OFF

GSK To Buy US Cancer Biotech IDRx For Up To $1.15 Billion (1)

2 weeks from now

2 days ago · GSK Plc agreed to buy US biotech IDRx for as much as $1.15 billion to gain new cancer medicines. The UK drugmaker will pay $1 billion upfront for IDRx, whose lead drug for …

bloomberglaw.com

$1.15
OFF

GSK To Buy US Biotech Firm IDRx For Up To $1.15 Billion

2 weeks from now

2 days ago · (Reuters) -British drugmaker GSK said on Monday that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical firm IDRx, which is developing a treatment for a …

investing.com

$1.15
OFF

GSK To Buy US Biotech Firm IDRx For Up To $1.15 Billion

2 weeks from now

2 days ago · British drugmaker GSK agrees to acquire Boston-based biopharmaceutical firm IDRx for up to $1.15 billion, with an initial $1 billion payment. IDRx develops a treatment for …

indiatimes.com

100%
OFF

GSK Enters Agreement To Acquire IDRx, Inc. - Morningstar

2 weeks from now

2 days ago · Under the terms of the agreement, GSK will acquire one hundred percent (100%) of the outstanding equity interests (including all options and other incentive equity) in IDRx for up …

morningstar.com

$1.15
OFF

GSK To Buy U.S. Rare Tumor Specialist IDRx For Up To $1.15 Billion

2 weeks from now

2 days ago · GSK is buying privately-owned U.S. rare-tumor specialist IDRx for up to $1.15 billion, boosting its gastrointestinal cancer portfolio. The pharmaceutical giant said Monday that it will …

morningstar.com

100%
OFF

IDRx To Be Acquired By GSK For $1 Billion Upfront, And Additional …

2 weeks from now

2 days ago · Under the terms of the agreement, GSK will acquire one hundred percent (100%) of the outstanding equity interests (including all options and other incentive equity) in IDRx for up …

goodwinlaw.com

100%
OFF

GSK Enters Agreement To Acquire IDRx, Inc. – IDRx

2 weeks from now

2 days ago · Under the terms of the agreement, GSK will acquire one hundred percent (100%) of the outstanding equity interests (including all options and other incentive equity) in IDRx for up …

idrx.com

$1.15
OFF

GSK To Acquire IDRx For $1.15bn — Financier Worldwide

2 weeks from now

1 day ago · BY Richard Summerfield Drug manufacturer GSK has agreed to acquire US biopharmaceutical firm IDRx, which is developing a therapy for the treatment of …

financierworldwide.com

$1.15
OFF

GSK To Buy Boston-based IDRx For $1.15 Billion - MSN

2 weeks from now

GSK (NYSE:GSK) finalized the deal to acquire Boston-based, clinical-stage biopharmaceutical company—IDRx for a total of up to $1.15 billion cash consideration. Under the agreement …

msn.com

$1.15
OFF

GSK To Acquire GIST Drug Developer IDRx For Up To $1.15 Bln Cash

2 weeks from now

2 days ago · (RTTNews) - British drug maker GSK plc (GSK.L, GSK) Monday announced that it has signed an agreement to acquire IDRx, a Boston-based, clinical-stage biopharmaceutical …

nasdaq.com

100%
OFF

GSK To Acquire IDRx For Upto USD 1.15 Billion

2 weeks from now

1 day ago · Under the terms of the agreement, GSK will acquire one hundred percent (100%) of the outstanding equity interests (including all options and other incentive equity) in IDRx for up …

medicaldialogues.in

$1.15
OFF

GSK Acquiring US-Based IDRx For Up To $1.15 Billion

2 weeks from now

2 days ago · -- GSK has agreed to acquire Boston-based IDRx for up to $1.15 billion as the British drugmaker looks to expand its gastrointestinal cancer portfolio, the companies said Monday. …

marketscreener.com

$1.15
OFF

British Pharma Giant GSK To Acquire U.S. Drug Developer IDRx

2 weeks from now

1 day ago · British pharma giant GSK to acquire U.S. drug developer IDRx in $1.15 billion deal

fortune.com

100%
OFF

GSK Enters Agreement To Acquire IDRx, Inc. - Stocktitan.net

2 weeks from now

2 days ago · Under the terms of the agreement, GSK will acquire one hundred percent (100%) of the outstanding equity interests (including all options and other incentive equity) in IDRx for up …

stocktitan.net

$1.15
OFF

GSK's $1.15 Billion Bet On IDRx: A Strategic Pivot In

2 weeks from now

2 days ago · British pharma giant GSK plans to acquire Boston-based IDRx for up to $1.15 billion, enhancing its gastrointestinal cancer portfolio. This strategic move aims to innovate cancer …

stockinvest.us

FAQs about GSK to buy US biotech firm IDRx for up to $1.15 billion | Reuters Coupon?

Will GSK pay $115 billion to buy idrx?

(Reuters) -British drugmaker GSK said on Monday that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical firm IDRx, which is developing a treatment for a rare type of tumour. IDRx, a privately held biotechnology firm, is developing a therapy for the treatment of gastrointestinal stromal tumours. ...

What is idrx's deal with GSK?

IDRx, a privately held biotechnology firm, is developing a therapy for the treatment of gastrointestinal stromal tumours. The deal, which comprises an upfront payment of $1 billion, will add to GSK's growing portfolio in gastrointestinal cancers. ...

Why did GSK acquire idrx-42?

“IDRX-42 complements our growing portfolio in gastrointestinal cancers. This acquisition is consistent with our approach of acquiring assets that address validated targets and where there is clear unmet medical need, despite existing approved products.” said Luke Miels, Chief Commercial Officer, GSK. ...

Who owns idrx?

IDRx counts Andreessen Horowitz, Casdin Capital, Nextech Invest, Forge Life Science Partners, and RA Capital Management among its investors. GSK (GSK) has agreed to acquire Boston-based IDRx for up to $1.15 billion as the British drugmaker looks to expand its gastrointestinal cancer portfolio, the companies said Monday. ...

Will GSK advance idrx-42 for patients with Gist?

"We are looking forward to working with GSK to advance IDRX-42 for patients with GIST given there have been no major advances to the standard of care for almost 20 years," IDRx Chief Executive Tim Clackson said. ...

Is idrx-42 a fast track orphan drug?

The US Food and Drug Administration has granted IDRX-42 fast track designation and orphan drug designations for the treatment of GIST, the companies said. ...